References
1. Foster, C., L. Smith, and R. Alemzadeh, Excess serum uric acid is
associated with metabolic syndrome in obese adolescent patients.
2. Liu, F., et al., Hyperuricemia and its association with adiposity and
dyslipidemia in Northwest China: results from cardiovascular risk survey
in Xinjiang (CRS 2008-2012). Lipids Health Dis, 2020. 19 (1): p.
58.
3. Derosa, G., P. Maffioli, and A. Sahebkar, Plasma uric acid
concentrations are reduced by fenofibrate: A systematic review and
meta-analysis of randomized placebo-controlled trials. Pharmacol Res,
2015. 102 : p. 63-70.
4. Katsiki, N., et al., Hyperuricaemia and non-alcoholic fatty liver
disease (NAFLD): a relationship with implications for vascular risk?
Curr Vasc Pharmacol, 2011. 9 (6): p. 698-705.
5. Catanzaro, R., et al., Non-alcoholic fatty liver disease: correlation
with hyperuricemia in a European Mediterranean population. Acta Clin
Belg, 2020: p. 1-6.
6. Khedr, N.F., A.M. Ebeid, and R.M. Khalil, New insights into weight
management by orlistat in comparison with cinnamon as a natural lipase
inhibitor. Endocrine, 2020. 67 (1): p. 109-116.
7. Holmback, U., et al., Effects of a novel combination of orlistat and
acarbose on tolerability, appetite, and glucose metabolism in persons
with obesity. Obes Sci Pract, 2020. 6 (3): p. 313-323.
8. Chales, G., How should we manage asymptomatic hyperuricemia? Joint
Bone Spine, 2019. 86 (4): p. 437-443.
9. Norgren, S., et al., Orlistat treatment in obese prepubertal
children: a pilot study. Acta Paediatrica, 2003. 92 (6): p.
666-670.
10. Diamanti-Kandarakis, E., et al., Short-term effect of orlistat on
dietary glycotoxins in healthy women and women with polycystic ovary
syndrome. Metabolism, 2006. 55 (4): p. 494-500.
11. Moher, D., et al., Preferred reporting items for systematic review
and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev, 2015.4 : p. 1.
12. Higgins, J.P., et al., Cochrane handbook for systematic reviews of
interventions. 2019: John Wiley & Sons.
13. Higgins, J.P., et al., The Cochrane Collaboration’s tool for
assessing risk of bias in randomised trials. Bmj, 2011. 343 : p.
d5928.
14. DerSimonian, R. and R. Kacker, Random-effects model for
meta-analysis of clinical trials: an update. Contemp Clin Trial 28 (2):
105–114. 2007.
15. Hozo, S.P., B. Djulbegovic, and I. Hozo, Estimating the mean and
variance from the median, range, and the size of a sample. BMC medical
research methodology, 2005. 5 (1): p. 13.
16. Higgins, J.P. and S.G. Thompson, Quantifying heterogeneity in a
meta-analysis. Stat Med, 2002. 21 (11): p. 1539-58.
17. Egger, M., et al., Bias in meta-analysis detected by a simple,
graphical test. Bmj, 1997. 315 (7109): p. 629-634.
18. Duval, S. and R. Tweedie, Trim and fill: A simple funnel-plot-based
method of testing and adjusting for publication bias in meta-analysis.
Biometrics, 2000. 56 (2): p. 455-63.
19. Borenstein, M., et al., Comprehensive meta-analysis version 2.
Biostat. Englewood NJ, 2005.
20. Guy‐Grand, B., et al., Effects of orlistat on obesity‐related
diseases–a six‐month randomized trial. Diabetes, Obesity and
Metabolism, 2004. 6 (5): p. 375-383.
21. Didangelos, T.P., et al., The ORLIstat and CArdiovascular risk
profile in patients with metabolic syndrome and type 2 DIAbetes
(ORLICARDIA) Study. Curr Med Res Opin, 2004. 20 (9): p.
1393-401.
22. Cocco, G., S. Pandolfi, and V. Rousson, Sufficient weight reduction
decreases cardiovascular complications in diabetic patients with the
metabolic syndrome. Heart Drug, 2005. 5 (2): p. 68-74.
23. Filippatos, T.D., et al., Effect of orlistat, micronised fenofibrate
and their combination on metabolic parameters in overweight and obese
patients with the metabolic syndrome: the FenOrli study. Curr Med Res
Opin, 2005. 21 (12): p. 1997-2006.
24. Nakou, E.S., et al., The effect of orlistat and ezetimibe, alone or
in combination, on serum LDL and small dense LDL cholesterol levels in
overweight and obese patients with hypercholesterolaemia. Curr Med Res
Opin, 2008. 24 (7): p. 1919-29.
25. Song, J., et al., Effect of orlistat or metformin in overweight and
obese polycystic ovary syndrome patients with insulin resistance.
Gynecol Endocrinol, 2018. 34 (5): p. 413-417.
26. Ye, J., et al., Effect of orlistat on liver fat content in patients
with nonalcoholic fatty liver disease with obesity: assessment using
magnetic resonance imaging-derived proton density fat fraction. Therap
Adv Gastroenterol, 2019. 12 : p. 1756284819879047.
27. Yeo, C., et al., Impact of bariatric surgery on serum uric acid
levels and the incidence of gout—A meta‐analysis. Obesity Reviews,
2019. 20 (12): p. 1759-1770.
28. Chen, S., et al., Association between serum uric acid levels and
dyslipidemia in Chinese adults: A cross-sectional study and further
meta-analysis. Medicine (Baltimore), 2020. 99 (11): p. e19088.
29. Kane, J.A., et al., Cardiovascular Risk Reduction Associated with
Pharmacological Weight Loss: A Meta-Analysis. Int J Clin Res Trials,
2019. 4 (1).
30. Dai, H.X., et al., Higher Levels of High-Sensitivity C-Reactive
Protein Is Positively Associated with the Incidence of Hyperuricemia in
Chinese Population: A Report from the China Health and Retirement
Longitudinal Study. Mediators Inflamm, 2020. 2020 : p. 3854982.
31. Carnicelli, A.P., et al., Elevated Uric Acid Prevalence and Clinical
Outcomes in Patients with Heart Failure with Preserved Ejection
Fraction: Insights from RELAX. Am J Med, 2020.
32. Derosa, G., P. Maffioli, and A. Sahebkar, Improvement of plasma
adiponectin, leptin and C-reactive protein concentrations by orlistat: a
systematic review and meta-analysis. Br J Clin Pharmacol, 2016.81 (5): p. 819-34.
Table 1.Characteristices of the included studies